Role of tixagevimab-cilgavimab in preventing SARS-CoV-2 in hematopoietic stem cell transplant and chimeric antigen receptor T-cell therapy recipients

J Med Virol. 2023 Aug;95(8):e29027. doi: 10.1002/jmv.29027.
No abstract available

Publication types

  • Letter

MeSH terms

  • COVID-19* / prevention & control
  • Cell- and Tissue-Based Therapy
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Receptors, Chimeric Antigen*
  • SARS-CoV-2
  • Transplant Recipients

Substances

  • tixagevimab
  • cilgavimab
  • Receptors, Chimeric Antigen